AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

PCSK9 Inhibitor Use and Risk of Major Amputation and All-Cause Mortality in Chronic Limb-Threatening Ischemia

By Mehdipournamdar Z, Yahyavi A, Hussein L et al.

Introduction: Chronic limb-threatening ischemia (CLTI) is the end-stage form of peripheral artery disease (PAD) and places a substantial burden on the healthcare system. These patients are at high risk of major adverse limb events, highlighting the need for effective medical therapies to modify disease progression in advanced PAD. Proprotein convertase subtilisin/kexin type 9 ( PCSK9) inhibitors are a class of medications used for reducing low-density lipoprotein cholesterol, and their role in lipid lowering and reducing adverse cardiovascular events is well established. Some studies have also suggested favorable limb outcomes of PCSK9 inhibitors in PAD patients, but data in patients with CLTI remain limited. This study evaluated the association between PCSK9 inhibitor use and the risks of major amputation and all-cause mortality in patients with CLTI. Research Question: What is the association between PCSK9 inhibitor use and major amputation and all-cause mortality in patients with CLTI? Methods/Approach: A retrospective cohort study was conducted using the real-world clinical data platform, TriNetX Network. Adult patients with CLTI were identified. Patients in the exposure group were required to have received evolocumab or alirocumab after CLTI diagnosis. Propensity score matching was performed using demographic characteristics, comorbidities, laboratory data, and the use of other medications including other lipid-lowering therapies. Outcomes were major amputation and allcause mortality, which were assessed at 3 months and up to 5 years. Cox proportional hazards models, Kaplan-Meier curves, and log-rank tests were used for analysis. Figures were generated using R 4.5.2. Results/Data: A total of 2,650 patients with CLTI receiving PCSK9 inhibitors were identified, compared with 219,098 CLTI patients not treated with this drug class. After propensity score matching, 2,638 patients remained in each cohort. At five years, PCSK9 inhibitor therapy was associated with a significantly reduced risk of major amputation (hazard ratio, [HR] 0.559, 95% CI 0.417–0.748, log-rank p < 0.001) and all-cause mortality (HR 0.622, 95% CI 0.540–0.717, log-rank p < 0.001). Conclusion: Among patients with CLTI, PCSK9 inhibitor use was associated with lower risks of major amputation and all-cause mortality over 5 years. These findings should be confirmed in prospective studies.

doi.org/10.1161/circ.154.suppl_1.13976Interventions

AgingResearch.News